Zimberelimab
Zimberelimab is a pharmaceutical drug with 50 clinical trials. Currently 32 active trials ongoing. Historical success rate of 72.7%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
22
Early Stage
25
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
61.5%
8 of 13 finished
38.5%
5 ended early
32
trials recruiting
50
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Clinical Trials (50)
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
AB154 Combined With AB122 for Recurrent Glioblastoma
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 50